Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Urvi Shah MD

Urvi A. Shah MD

Assistant Attending, Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; Assistant Professor of Medicine, Weill Cornell Medical College, New York, New York

Dr. Urvi A. Shah, MD, is an Assistant Attending in the Myeloma Service at Memorial Sloan Kettering Cancer Center (MSK) and Assistant Professor of Medicine at Weill Cornell Medicine. She completed fellowships in hematology/oncology at Montefiore Medical Center, and in cancer immunotherapy at MSK and the Parker Institute for Cancer Immunotherapy in New York. She is board certified in Internal Medicine, Hematology and Medical Oncology.

Her clinical practice includes all plasma cell disorders and her research interests include modifiable risk factors (diet, metabolism, and the microbiome) and immune therapies in cancer. She opened the first pilot nutrition trial in plasma cell disorders to date (NUTRIVENTION; NCT04920084) in 2021 that completed enrollment. She has 3 other NUTRIVENTION/immune therapy investigator-initiated trials (NCT05640843, NCT04497961, NCT04174196) currently enrolling. Dr. Shah has been supported by career development awards from the National Cancer Institute Paul Calabresi K12, International Myeloma Society and American Society of Hematology Scholar Award. Dr. Shah has published first author papers in prominent journals such as Blood and Clinical Cancer Research amongst others and has been an invited speaker and session chair nationally and internationally.

Disclosures

U.A.S. reports grants from MSK Paul Calabresi Career Development Award for Clinical Oncology K12CA184746, Paula and Rodger Riney Foundation, Parker Institute for Cancer Immunotherapy at MSK, HealthTree Foundation, International Myeloma Society, American Society of Hematology Scholar Award and Allen Foundation Inc, as well as non-financial support from American Society of Hematology Clinical Research Training Institute and TREC Training Workshop R25CA203650 (PI: Melinda Irwin). U.A. Shah also reports other research support from Celgene/BMS and Janssen to the institution; personal fees from ACCC, MashUp MD, Janssen Biotech, Sanofi, BMS, MJH LifeSciences, Intellisphere, Phillips Gilmore Oncology Communications, RedMedEd and i3Health.

Recent Contributions to PracticeUpdate:

  1. Dose/Exposure Relationship of Exercise and Distant Recurrence in Patients With Primary Breast Cancer
  2. Safety and Efficacy of Streptococcus salivarius K12 for Treatment of Oral Mucositis Associated With Radiotherapy for Head and Neck Tumors
  3. The Effect of Diet on Breast Cancer Recurrence

Most Read This Week

Recently Updated